229 related articles for article (PubMed ID: 26353782)
1. DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines.
Salim H; Zong D; Hååg P; Novak M; Mörk B; Lewensohn R; Lundholm L; Viktorsson K
BMC Cancer; 2015 Sep; 15():628. PubMed ID: 26353782
[TBL] [Abstract][Full Text] [Related]
2. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
[TBL] [Abstract][Full Text] [Related]
3. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells.
Mohammed Ael S; Eguchi H; Wada S; Koyama N; Shimizu M; Otani K; Ohtaki M; Tanimoto K; Hiyama K; Gaber MS; Nishiyama M
Exp Lung Res; 2012 Nov; 38(9-10):463-74. PubMed ID: 23098063
[TBL] [Abstract][Full Text] [Related]
4. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of Dickkopf-1 among non-small cell lung cancer cells.
Xiang XJ; Liu YW; Chen DD; Yu S
Mol Med Rep; 2015 Aug; 12(2):1935-40. PubMed ID: 25901391
[TBL] [Abstract][Full Text] [Related]
6. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
Bar J; Gorn-Hondermann I; Moretto P; Perkins TJ; Niknejad N; Stewart DJ; Goss GD; Dimitroulakos J
Clin Lung Cancer; 2015 Nov; 16(6):e121-9. PubMed ID: 25703099
[TBL] [Abstract][Full Text] [Related]
7. Dickkopf-3 (Dkk3) induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/β-catenin pathway.
Wang Z; Ma LJ; Kang Y; Li X; Zhang XJ
Oncol Rep; 2015 Mar; 33(3):1097-106. PubMed ID: 25573172
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells.
Ikuta K; Takemura K; Kihara M; Nishimura M; Ueda N; Naito S; Lee E; Shimizu E; Yamauchi A
Oncol Rep; 2005 Feb; 13(2):217-22. PubMed ID: 15643501
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of circular RNA expression profiles in cisplatin-resistant non-small cell lung cancer cell lines.
Song L; Cui Z; Guo X
Acta Biochim Biophys Sin (Shanghai); 2020 Sep; 52(9):944-953. PubMed ID: 32716023
[TBL] [Abstract][Full Text] [Related]
10. Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
Ryan SL; Beard S; Barr MP; Umezawa K; Heavey S; Godwin P; Gray SG; Cormican D; Finn SP; Gately KA; Davies AM; Thompson EW; Richard DJ; O'Byrne KJ; Adams MN; Baird AM
Lung Cancer; 2019 Sep; 135():217-227. PubMed ID: 31446998
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
12. Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1.
Gosepath EM; Eckstein N; Hamacher A; Servan K; von Jonquieres G; Lage H; Györffy B; Royer HD; Kassack MU
Int J Cancer; 2008 Nov; 123(9):2013-9. PubMed ID: 18688867
[TBL] [Abstract][Full Text] [Related]
13. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
Sui C; Meng F; Li Y; Jiang Y
J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
[TBL] [Abstract][Full Text] [Related]
14. Dickkopf-1 is oncogenic and involved in invasive growth in non small cell lung cancer.
Li S; Qin X; Guo X; Cui A; He Y; Wei S; Wang X; Shan B
PLoS One; 2013; 8(12):e84944. PubMed ID: 24391982
[TBL] [Abstract][Full Text] [Related]
15. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules.
Duan S; Tsai Y; Keng P; Chen Y; Lee SO; Chen Y
Oncotarget; 2015 Sep; 6(29):27651-60. PubMed ID: 26313152
[TBL] [Abstract][Full Text] [Related]
16. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review).
Wang G; Reed E; Li QQ
Oncol Rep; 2004 Nov; 12(5):955-65. PubMed ID: 15492778
[TBL] [Abstract][Full Text] [Related]
18. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.
Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y
Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668
[TBL] [Abstract][Full Text] [Related]
19. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines.
Cetintas VB; Kucukaslan AS; Kosova B; Tetik A; Selvi N; Cok G; Gunduz C; Eroglu Z
Cell Biol Int; 2012 Mar; 36(3):261-5. PubMed ID: 22397496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
